Hypoxia: a barricade to conquer the pancreatic cancer

Abstract

Pancreatic cancer (PC) remains one of the most extremely lethal malignancies worldwide due to late diagnosis and early metastasis, with a 1-year overall survival rate of approximately 20%. The hypoxic microenvironment, induced by intratumoral hypoxia, promotes tumor invasion and progression, leading to chemotherapy or radiotherapy resistance and eventual mortality after treatment of PC. However, the role of the hypoxic microenvironment in PC is complicated and requires further investigation. In this article, we review recent advances regarding the regulation of malignant behaviors in PC, which provide insight into the potential of hypoxic microenvironment activation therapy for the therapeutic agents.

Introduction

Pancreatic cancer (PC) is the fourth leading cause of cancer-related mortality in the United States, with an overall survival rate of only 8% [1]. However, clinical outcomes are quite modest due to acquired and inherent chemoresistance. Although research advances have been made to develop chemotherapy options and certain biomarkers have been used for patient-targeted therapeutic strategies, there has been no significant improvement in preventing PC progression and metastasis. The limited availability of diagnostic channels and the use of surgery as the only existing curative option with an overall survival of only 10% of patients diagnosed contribute to the terrible nature of this disease [2].

Increasing interest has been concentrated on the tumor microenvironment of PC. Cancer cells, stromal cells, and extracellular components are significant constituents of the tumor microenvironment. Compared with most solid tumors, PC is recognized as lowest level of oxygen [3]. This is possibly a common phenomenon given the fibrotic vasculature, which is ineffective. Recent studies have begun to delineate that the hypoxia microenvironment, a fundamental characteristic in PC, plays a critical role in PC development [4]. In this review, we summarize the current information about the role of hypoxia in promoting the progression of PC and provide new insights for developing targeted therapies for PC.

Hypoxia promotes tumorigenesis in PC

Hypoxia, which is defined as reduced oxygen levels, occurs in 50–60% of locally advanced solid tumors, including PC. In PC, there is a reduction in the tissue oxygen partial pressure in tumors, with a median partial pressure of oxygen (PO₂) of 0–5.3 mmHg (0–0.7%); this is distinct from the median PO₂ in normal pancreas (24.3–92.7 mmHg, 3.2–12.3%) [3, 5]. A signature feature of PC is the formation of a compressed desmoplastic stroma with poor tumor cellularity that surrounds the tumor [6]. Hypoxia gives rise to several changes in gene expression in tumor cells. This adaptive response to hypoxia is activated by transcription factors such as hypoxia-inducible factors (HIFs), which in turn stimulate the expression of related genes involved in angiogenesis and glycolysis, thus prompting PC cells to adapt to the hypoxic conditions.

HIFs are heterodimeric transcription factors composed of an unstable α subunit (HIFα) and a stable β subunit (HIFβ) [7]. In normoxia, HIFα protein subunits have a rapid half-life (< 5 min) because they are continually transcribed and rapidly degraded. This turnover is mediated by the posttranslational hydroxylation of highly conserved proline residues (Pro⁵⁶⁴ and Pro⁴⁰² in HIF1α, Pro⁴⁰⁵ and Pro⁵³¹ in HIF2α) within their N-terminal oxygen-dependent degradation domains (NODDs) and C-terminal oxygen-dependent degradation domains (CODDs) by proteins containing proline hydroxylase domains (PHDs) [8]. Under hypoxia, HIFα subunits translocate into the nucleus to bind with HIFβ due to the suppression of factor inhibiting HIF (FIH) and PHD activities. The heterodimeric HIFα:HIFβ transcription factor complex binds to hypoxia-responsive elements (HREs) of its target genes and adjusts their transcription [9].

Previous studies have demonstrated that HIF1 could induce a large number of downstream transactivating genes encoding glucose transporters and glycolytic enzymes in response to hypoxia [10]. With the decrease in oxygen levels, the production of adenosine triphosphate (ATP) changes from the oxidative phosphorylation pathway to the oxygen-independent pathway of cytoplasmic glycolysis, a phenomenon known as the Warburg effect [11, 12]. Regarding the generation of ATP, glycolysis is less efficient than oxidative phosphorylation. However, due to the increase in glycolytic enzyme activity, ATP production could be sustained by sufficient glycolysis. To increase the glucose supply, HIF1 promotes the increase in the transcription of glucose transporters 1 and 3 (GLUT1 and GLUT3) and facilitates the production of pyruvate and lactate dehydrogenase [13]. The lactate generated from glycolysis is further utilized as energy for surrounding cells and weakens the production of T-cell cytokines. Pyruvate dehydrogenase kinase 1 (PDK1) can prevent pyruvate dehydrogenase from using pyruvate to fuel the mitochondrial tricarboxylic acid cycle (TCA cycle), causing a drop in mitochondrial oxygen consumption [14]. In a hypoxic environment, low oxygen levels cannot support oxidative phosphorylation in mitochondria, and HIF1 reduces mitochondrial oxygen consumption via activation of pyruvate dehydrogenase kinase 1 (PDK1) [15]. Another characteristic of a hypoxic environment in PC is an increase in tumor cell migration. There are multiple pathways activated by HIF1 that promote epithelial to mesenchymal transition (EMT), which is the transformation of cells from a polarized epithelial phenotype to fibroblast-like mesenchymal phenotype. Hypoxia and HIFs promote EMT by upregulating transcriptional repressors such as SNAIL, TWIST, and ZFHX1B and induce degradation of the extracellular matrix (ECM) via various proteins such as cathepsin and matrix metalloproteinase-1 and -2. In addition, hypoxia-induced expression of vascular endothelial growth factor (VEGF) promotes lymphangiogenesis and angiogenesis, which drive tumor cell intravasation and dissemination [16].

Furthermore, an increasing number of findings supports the essential role of noncoding RNAs because they are aberrantly expressed under hypoxia and participate in tumor cell migration and metastasis. Based on the complicated roles of noncoding RNAs in tumor metastasis, targeting them in signaling pathways related to hypoxia has been emphasized recently [17]. Noncoding RNAs include microRNAs (miRNAs, 18–22 nucleotide) and long noncoding RNAs (lncRNAs, ≥ 200 nucleotides). MiRNA research offers molecular insight into tumor aggression and carcinogenesis. The mature form of these small noncoding RNAs fit into the RNA-induced silencing complex [18]. MiRNAs cause either translational inhibition or mRNA degradation by binding to a conserved sequence of the 3′untranslated region of the target gene. Prior studies have noted evidence of the dysregulation of the expression of specific miRNAs in PC. Given the various roles of miRNAs in multiple aspects of cancer biology, it could conceivably be hypothesized that they also play a major role in the neoplastic hypoxia microenvironment [19]. Recently, a subset of hypoxia-inducible miRNAs have been reported to be abnormally expressed in PC, suggesting that inducing the expression of these miRNAs may influence important target genes involved in tumor survival, invasion, and metastasis [20]. Migration and invasion inhibitory protein (MIIP) has recently been noted as an inhibitor of tumor development. Niu et al. reported that HIF1 could regulate MIIP expression at the posttranscriptional level by upregulating miR-646 transcription. Dysregulated miR-646 and MIIP expression were correlated with tumor stage, metastasis, and lymphatic invasion in PC patients [21]. Mitochondrial fission is an important procedure for the development and progression of PC. Suppressed mitochondrial fission could lead to a reduction in proapoptotic protein content, which hampers mitochondria-related apoptosis pathways. A recent in vitro study described mitochondrial fission as a tumor suppression process that could be regulated by the HIF1/miR-125a/Mfn2 pathway to restrict PANC-1 cell survival and migration [22]. LncRNAs may act as transcriptional modulators, enhancers, and molecular decoys for miRNAs and protein–RNA interactions [23]. LncRNAs can also act as an oncogene or tumor suppressor via modulation of cancer-related signaling pathways in various manners [24]. ZEB1, a key regulator of EMT, could be activated by the binding of lncRNA-BX111887 (BX111) to the promoter region of the transcriptional factor Y-box protein (YB1). The hypoxic microenvironment is a crucial factor in the generation of pathological EMT-induced BX111 transcription via HIF1 overexpression [25]. Furthermore, lncRNAs can work as competing endogenous RNAs (ceRNAs) or “RNA sponges” that interact with miRNAs and reduce their regulatory activity on target mRNAs. NORAD (annotated as LINC00657 in RefSeq), a highly conserved mammalian noncoding RNA, could act as in an oncogenic capacity in the pathogenesis of PC via competition for miR-125a-3p, was upregulated during hypoxia and promoted EMT in PC cells [26]. These results are similar to a study reported by Ou et al. FEZF1-AS1, a recently described oncogenic long noncoding RNA, has been associated with poor prognosis of gastric cancer and shown to accelerate progression in pancreatic ductal adenocarcinoma. Ou et al. reported that FEZF1-AS1 could stimulate PC cell proliferation and invasion via the miR-142/HIF1α axis under hypoxic conditions [27].

Role of hypoxia and HIF in drug resistance

In the past two decades, there was no significant progress in the prognosis of PC. Surgery is the only curative option, but 5-year survival rates after surgical resection alone are still pessimistic (approximately 15–27%; median survival period, 17–23 months) [28]. The combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and nab-paclitaxel plus gemcitabine has been administered as a first-line treatment in patients with metastatic PC [29, 30]. However, the current treatments are correlated with a median progression-free survival of approximately 6 months, and fewer than 10% of patients are alive 5 years after initial diagnosis [31]. Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms, including the following (Fig. 1):

1. Extrinsic resistance. Hypoxia in PC is produced partly through fibrogenic effects of cancer-associated fibroblasts (CAFs) and dense ECM components [32]. Elevated interstitial fluidic pressure and inappropriate blood flow lead to hypoxic niches in the tumors and a decrease in circulating drug perfusion into the tumor. The ECM is a complicated network of macromolecules that provides a substantial scaffold to maintain tissue architecture [33]. All the proteins, glycoproteins, and polysaccharide elements of the ECM are generally produced by epithelial and stromal cells, which account for the fibrotic area in the PC. Posttranslational modifications of fibrillar collagens require the assistance of collagen-modifying enzymes, some of which are regulated by HIFs. Therefore, reducing tissue tension and intratumoral pressure by modifying the expression of HIFs may result in improved perfusion of chemotherapeutic agents and therapeutic response [34].

2. The regulation of drug efflux. A growing body of literature supports the participation of HIF1 in drug resistance by stating that HIF1 is able to stimulate the expression of the multidrug resistance 1 (MDR1) gene in response to hypoxia. MDR1, which is translated into the membrane-bound protein P-glycoprotein (P-gp), is associated with a family of ATP-binding cassette (ABC) transporters. P-gp can decrease the intracellular concentration of chemotherapeutic drugs, such as paclitaxel and anthracyclines, and can be used as a drug efflux pump [35].

3. Metabolic reprogramming. HIF manages a diverse range of metabolic pathways that are overactivated in cancer, such as mitochondrial activity, intracellular pH regulation, and glycolysis. Mitochondria also plays an important role in cell death by regulating intrinsic apoptotic pathways and producing reactive oxygen species (ROS) [36]. Experimental data for enhanced ROS formation in response to chemotherapy under hypoxic conditions were recently provided by Maher Y. Abdalla et al. Heme oxygenase-1 (HO-1) is the rate-limiting enzyme of cellular heme catabolism. This microsomal enzyme acts on heme moieties to generate equimolar amounts of carbon monoxide and iron. These HO-1 degradation products were shown to modulate metabolism and promote tumor growth. Maher Y. Abdalla et al. suggested that hypoxia could upregulate HO-1 expression in PC cells. Under in vitro hypoxia conditions, the application of the HO-1 inhibitors zinc protoporphyrin (ZnPP) and tin protoporphyrin IX (SnPP) could increase ROS production, enhance apoptosis, inhibit PC cell proliferation, and sensitize these cells to gemcitabine [37]. Similarly, enolase 1 (ENO1), a multifunctional glycolytic enzyme, sensitizes PC cells to hypoxia-induced resistance by altering ROS homeostasis. The mechanisms might be related to the influence of increase ROS on apoptosis and cell cycle progression [38].

4. Hypoxia-driven alterations in apoptosis and cell survival. Some studies have shown that HIF1 could regulate proapoptotic factors (BNIP3, NIX, and NOXA) as well as antiapoptotic factors (Bcl-xL, Bcl-2, Bid, Mcl-1, NF-κB, and p53) to modulate defective apoptosis and changes in cell cycle progression [39–41]. HIF1 functions as a strong suppressor of apoptosis, and functional intervention with HIF1 in PC cells results in changes in programmed cell death upon treatment with chemotherapeutic agents. For example, Nagaraju et al. suggested that inhibition of HSP90 with ganetespib, a small-molecule inhibitor (SMI) of HSP90, downregulated the expression of HIF1 and induced the activation of signaling pathways, including proliferative, angiogenic, and antiapoptotic pathways. Notably, the promotion of apoptosis was also observed in gemcitabine- and 5-FU-resistant pancreatic cell lines when HSP90 was inhibited [42].

5. Inhibition of DNA damage. DNA damage remains the foundation of many cancer treatments, and inducing DNA damage is the fundamental mode of action for the majority of classical chemotherapeutic agents. Despite their effectiveness in suppressing tumors, DNA repair pathways can also allow tumor cells to escape from genotoxic assault [43]. Complementing these results, a study by FF Blanco et al. showed that the proto-oncogene proviral integration site for Moloney murine leukemia virus 1 (PIM1), a serine–threonine kinase, could regulate hypoxia-induced chemoresistance by phosphorylating targets and promoting apoptosis. Upon PIM1-mediated phosphorylation of CDC25a, PC cells undergo dynamic reprogramming that allows them to acquire a chemoresistant response via DNA repair mechanisms. HuR (Hu antigen R; ELAVL1), an RNA-binding protein fundamental to posttranscriptional gene regulation in PC, is an element of the embryonic lethal and Drosophila-like protein family. HuR can mediate the regulation of PIM1 and consequently prevent DNA damage induced by chemotherapeutics. Importantly, inhibiting HuR could reverse hypoxia-induced PIM1 overexpression and notably enhance PC cell sensitivity to oxaliplatin and 5-fluorouracil in a hypoxic microenvironment [44].

6. Hypoxia induction of stemness. Cancer stem cells (CSCs) are a group of cancer cells with stem cell-like characteristics. In solid tumors, CSCs are functionally defined by their traits of self-renewal, differentiation, and tumor generation [45, 46]. If the CSC subpopulation is not eliminated during chemoradiotherapy of PC, tumor recurrence and subsequent clinical progression may manifest due to the drug resistance of CSCs. Components in the stromal microenvironment, such as pancreatic stellate cells (PSCs), endothelial cells and immune cells, could develop into an ideal niche for pancreatic CSCs [47]. Hypoxic niches further facilitate the remodeling of the ECM, and changes in biochemical secreted factors can promote tumor invasive capacities and tumorigenicity and help preserve progenitor CSCs. PC stem cell markers, such as ESA, CD133, CD24 and CD44, may be negative prognostic factors that are related to poor outcomes and resistance to standard treatment. Moreover, the abnormal activation of multiple signaling pathways in the hypoxic microenvironment, including the Wnt, Notch and PI3K/Akt/mTOR pathways, may play an important role in acquiring chemoresistance to gemcitabine through the induction of stemness [48]. Zhang et al. reported that the Akt/Notch1 signaling pathway intervened to induce gemcitabine resistance in PC via stemness induction, which was exacerbated by the universal hypoxic niche in cancer cells [49]. Additionally, CD133 is a transmembrane protein expressed in lipid rafts, with an extracellular ganglioside-binding domain and cytoplasmic activity akin to tyrosine phosphorylation [50]. By promoting HIF1α expression under hypoxia, CD133 could influence tumor cell migration and invasion through EMT gene expression. Confirmation of the CD133/HIF1α-signaling axis bolsters, the future possibility of a supplemental HIF1α inhibitor combined with conventional therapy to increase the efficacy of treating CD133⁺ CSCs in PC [51].

Fig. 1.

Summary of mechanisms and pathways underlying HIF-mediated chemotherapy resistance

Strategies to inhibit the HIF1 pathway

As the key factors that correlate with treatment resistance and PC, hypoxia and HIFs have attracted increasing attention. Because the key regulator during hypoxia is HIF, agents that can suppress its function are still eagerly anticipated and should be examined for clinical activity in PC. Minnelide, a water-soluble analog of triptolide that has potent antiproliferative activity against multiple tumor types, inhibits HIF1 transcriptional activity and decreases stemness in PC cells. A phase I dose escalation and pharmacokinetic study with single-agent minnelide were recently completed in patients with advanced gastrointestinal tumors [52]. In addition, minnelide is currently in phase II clinical trials for the treatment of PC, which has stimulated increased interest in this promising agent [53]. Digoxin, a well-known cardiac glycoside, was previously verified to be a potent inhibitor of hypoxia-induced HIF1α production. In an in vitro study, Zhou et al. reported that digoxin could be used as a potential sensitizer to reverse chemoresistance in PC, but there is no official clinical trial that confirms this activity [54]. Another compound extracted from melphalan, PX-478, which inhibits HIF1α expression in PC, resulted in reduced preclinical tumor growth but showed restricted clinical activity in a phase I study [55]. However, in a recent in vitro study, Lang et al. found that PX-478 plus arsenic trioxide (ATO) could be a promising strategy to promote ROS-induced apoptosis in the treatment of PC [56].

Conclusion

The contribution of the tumor microenvironment to the lethal outcomes of PC is substantial. One of the elements in the PC microenvironment is hypoxia, which shifts the expression patterns in cancer cells to reduce intrinsic and extrinsic damage originating from rapid tumor growth under disadvantageous conditions. It is noteworthy that tumor hypoxia and its main driver, HIFs, promote the capacity for PC invasiveness and metastasis by activating EMT- and CSC-related pathways, which all contribute to the aggressive phenotype of this disease. Furthermore, hypoxia regulates many important biological hallmarks of cancer, ranging from tumor cell differentiation and metabolic reprogramming to chemotherapy resistance. Despite significant advances in recent years, chemotherapy resistance and the subsequent need for novel therapeutic approaches remain the main barrier in clinical oncology. It is now commonly accepted that the specialized hypoxia microenvironment of PC is largely accountable for the insufficient in vivo efficacy of many treatments. To optimize the effects of these compounds, it is of chief importance to identify suitable patient subgroups and tumor cell subpopulations for precision medicine in PC. Moreover, identification of predictive markers for “hypoxia-based” substances and the development of combination therapies comprising multiple compounds that interfere with HIFs and hypoxia-related pathways with traditional chemotherapeutics are urgently needed to permit their investigation in clinical trials.

Abbreviations

ATP

Adenosine triphosphate

CAF

Cancer-associated fibroblast

CODD

C-terminal oxygen-dependent degradation domain

CSC

Cancer stem cell

ECM

Extracellular matrix

EMT

Epithelial to mesenchymal transition

ENO1

Enolase 1

HIF

Hypoxia-inducible factor

MDR1

Multidrug resistance 1

MIIP

Migration and invasion inhibitory protein

NODD

N-terminal oxygen-dependent degradation domain

PC

Pancreatic cancer

PDK1

Pyruvate dehydrogenase kinase 1

PHD

Proline hydroxylase domain

ROS

Reactive oxygen species

VEGF

Vascular endothelial growth factor

Funding

This study was jointly funded by the National Science Foundation for Distinguished Young Scholars of China (No. 81625016), the National Natural Science Foundation of China (No. 81602085 and 81902428) and the Shanghai Sailing Program (No. 17YF1402500 and 19YF1409400).

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest.